SynthesisEuropean journal of nuclear medicine and molecular imaging2021
PET/MRI in prostate cancer: a systematic review and meta-analysis.
Synthesis in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- Genomic classifiers and prognosis of localized prostate cancer: a systematic review.Prostate cancer and prostatic diseases · 2025Pooled it
- Magnetic resonance imaging (MRI) for local staging before salvage radical prostatectomy: a meta-analysis.World journal of urology · 2023Pooled it
- Diagnostic accuracy of fully hybrid [European journal of nuclear medicine and molecular imaging · 2024Trial
- Head-to-head comparison of MRI-based PI-RR scoring system and 68 Ga-PSMA-PET/CT: enhancing prostate cancer recurrence detection after radical prostatectomy.La Radiologia medica · 2026Article
- Predicting inguinal lymph node metastasis in penile squamous cell carcinoma, from imaging, molecular biomarkers to multimodal AI: a narrative review.Translational andrology and urology · 2026Review
- Visualizing extracellular vesicles in cancer: from biogenesis to theranostic applications.Journal of nanobiotechnology · 2026Review
- Diagnostic Accuracy of PSMA-PET/CT vs. mpMRI in Primary Staging of Intermediate- and High-Risk Prostate Cancer.Medical sciences (Basel, Switzerland) · 2026Article
- Review
- Multimodal data fusion: integrating PET/MRI and liquid biopsy for a holistic view of cancer biology.Frontiers in oncology · 2026Review
- Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy.European journal of nuclear medicine and molecular imaging · 2026Article
- Comparison of Magnetic Resonance Spectra Acquired With Hybrid PET/MR and Standalone MR Scanners.Journal of magnetic resonance imaging : JMRI · 2025Article
- Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers.Cancers · 2025Review
- The impact of short-term non-steroidal androgen antagonist therapy on PSMA expression and tumor cellularity studied with dynamic [EJNMMI research · 2025Article
- Biparametric magnetic resonance imaging-based radiomics model can improve the detection of dense and sparse prostate cancers.Quantitative imaging in medicine and surgery · 2025Article
- Discovery of tumour indicating morphological changes in benign prostate biopsies through AI.Scientific reports · 2025Article
- Diagnostic efficacy of [Discover oncology · 2025Article
- Dualistic Dynamics in Neuropsychiatry: From Monoaminergic Modulators to Multiscale Biomarker Maps.Biomedicines · 2025Article
- Preliminary clinical study of p-iodo benzoyl moiety-modified PSMA inhibitors and prospective comparison with 68Ga-PSMA-11.Scientific reports · 2025Article
- Advanced Nanomaterials for Cancer Therapy: Gold, Silver, and Iron Oxide Nanoparticles in Oncological Applications.Advanced healthcare materials · 2025Review
- PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn recent years, the clinical availability of scanners for integrated positron emission tomography (PET) and magnetic resonance imaging (MRI) has enabled the practical potential of multimodal, combined metabolic-receptor, anatomical, and functional imaging to be explored. The present systematic review and meta-analysis summarize the diagnostic information provided by PET/MRI in patients with prostate cancer (PCa). MATERIALS AND
methodsA literature search was conducted in three different databases. The terms used were "choline" or "prostate-specific membrane antigen - PSMA" AND "prostate cancer" or "prostate" AND "PET/MRI" or "PET MRI" or "PET-MRI" or "positron emission tomography/magnetic resonance imaging." All relevant records identified were combined, and the full texts were retrieved. Reports were excluded if (1) they did not consider hybrid PET/MRI; or (2) the sample size was < 10 patients; or (3) the raw data were not enough to enable the completion of a 2 × 2 contingency table.
resultsFifty articles were eligible for systematic review, and 23 for meta-analysis. The pooled data concerned 2104 patients. Initial disease staging was the main indication for PET/MRI in 24 studies. Radiolabeled PSMA was the tracer most frequently used. In primary tumors, the pooled sensitivity for the patient-based analysis was 94.9%. At restaging, the pooled detection rate was 80.9% and was higher for radiolabeled PSMA than for choline (81.8% and 77.3%, respectively).
conclusionsPET/MRI proved highly sensitive in detecting primary PCa, with a high detection rate for recurrent disease, particularly when radiolabeled PSMA was used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.